BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 567 filers reported holding BIO-TECHNE CORP in Q4 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $33,156,148 | -16.8% | 487,089 | -0.2% | 0.01% | -14.3% |
| Q2 2023 | $39,841,399 | +107962.1% | 488,073 | -1.8% | 0.01% | 0.0% |
| Q1 2023 | $36,869 | +10.0% | 496,956 | +22.9% | 0.01% | +7.7% |
| Q4 2022 | $33,516 | -99.9% | 404,401 | +279.7% | 0.01% | +8.3% |
| Q3 2022 | $30,247,000 | -20.4% | 106,505 | -2.9% | 0.01% | -20.0% |
| Q2 2022 | $38,016,000 | -33.3% | 109,669 | -15.7% | 0.02% | -16.7% |
| Q1 2022 | $56,982,000 | +8.3% | 130,026 | +27.9% | 0.02% | +12.5% |
| Q4 2021 | $52,606,000 | +2.8% | 101,684 | -3.7% | 0.02% | 0.0% |
| Q3 2021 | $51,162,000 | -11.5% | 105,582 | -17.7% | 0.02% | -5.9% |
| Q2 2021 | $57,793,000 | +3.9% | 128,356 | -11.8% | 0.02% | -5.6% |
| Q1 2021 | $55,605,000 | +27.8% | 145,589 | +6.3% | 0.02% | +20.0% |
| Q4 2020 | $43,498,000 | +98.6% | 136,980 | +55.0% | 0.02% | +87.5% |
| Q3 2020 | $21,898,000 | -9.5% | 88,393 | -3.5% | 0.01% | -20.0% |
| Q2 2020 | $24,199,000 | +45.2% | 91,637 | +4.2% | 0.01% | +25.0% |
| Q1 2020 | $16,670,000 | -29.8% | 87,916 | -18.7% | 0.01% | -11.1% |
| Q4 2019 | $23,730,000 | +3.7% | 108,101 | -7.6% | 0.01% | 0.0% |
| Q3 2019 | $22,882,000 | -13.0% | 116,942 | -7.3% | 0.01% | -10.0% |
| Q2 2019 | $26,289,000 | +6640.8% | 126,091 | +6323.4% | 0.01% | +400.0% |
| Q1 2019 | $390,000 | -5.6% | 1,963 | -2.9% | 0.00% | 0.0% |
| Q3 2018 | $413,000 | +38.1% | 2,021 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $299,000 | -0.3% | 2,021 | +1.9% | 0.00% | 0.0% |
| Q1 2018 | $300,000 | +16.7% | 1,983 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $257,000 | +7.1% | 1,983 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $240,000 | +3.0% | 1,983 | 0.0% | 0.00% | +100.0% |
| Q2 2017 | $233,000 | -82.3% | 1,983 | -84.7% | 0.00% | -87.5% |
| Q1 2017 | $1,320,000 | -19.1% | 12,984 | -18.1% | 0.01% | 0.0% |
| Q4 2016 | $1,631,000 | -7.1% | 15,862 | -1.1% | 0.01% | -20.0% |
| Q3 2016 | $1,756,000 | -2.9% | 16,040 | 0.0% | 0.01% | -9.1% |
| Q2 2016 | $1,809,000 | -13.0% | 16,040 | -27.1% | 0.01% | 0.0% |
| Q1 2016 | $2,079,000 | -42.5% | 21,998 | -45.3% | 0.01% | -42.1% |
| Q4 2015 | $3,618,000 | -2.7% | 40,198 | 0.0% | 0.02% | -9.5% |
| Q3 2015 | $3,717,000 | +11.0% | 40,198 | +18.2% | 0.02% | +16.7% |
| Q2 2015 | $3,349,000 | -1.8% | 34,015 | 0.0% | 0.02% | -5.3% |
| Q1 2015 | $3,411,000 | +8.5% | 34,015 | 0.0% | 0.02% | +5.6% |
| Q4 2014 | $3,143,000 | – | 34,015 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |